Vertex Pharma's combination cystic fibrosis therapy wins FDA nod

July 2 (Reuters) - Vertex Pharmaceuticals Inc's combination therapy for a rare lung disorder was approved by U.S. health regulators, extending the company's reach to now treat the most common form of genetic mutation responsible for cystic fibrosis.